FDA Reviewers Cast Doubt on Drug Candidate for Barth Syndrome
MedPage Today) — Ahead of an FDA advisory committee meeting on Thursday, agency reviewers cast doubt on the efficacy of elamipretide for Barth syndrome, an ultra-rare disease that has no approved treatments. In its new drug application, Stealth…
MedPage Today) — Ahead of an FDA advisory committee meeting on Thursday, agency reviewers cast doubt on the efficacy of elamipretide for Barth syndrome, an ultra-rare disease that has no approved treatments.
In its new drug application, Stealth…
Read More
About Author
